Amylyx Pharmaceuticals (AMLX) vs Dyne Therapeutics (DYN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Amylyx Pharmaceuticals (AMLX) has outperformed Dyne Therapeutics (DYN) over the past year, gaining 103.3% versus a gain of 14.5%. Amylyx Pharmaceuticals is the larger company by market cap ($3.44 billion vs $2.98 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMLX | DYN |
|---|---|---|
| Share price | $27.43 | $15.97 |
| Market cap | $3.44B | $2.98B |
| 1-day change | -2.18% | +3.70% |
| YTD return | +127.07% | -18.35% |
| 1-year return | +103.34% | +14.48% |
| 5-year return | — | +7.33% |
| EPS (TTM) | $-1.41 | $-3.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-144.74M | $-446.21M |
| 52-week high | $41.14 | $27.31 |
| 52-week low | $10.83 | $13.73 |
| Distance from 52-week high | -33.33% | -41.51% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +54.43% | +125.42% |
| Average volume | 2.33M | 2.77M |
| Shares outstanding | 125.51M | 186.75M |
| Employees | 136 | 289 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMLX has outperformed DYN by 88.9 percentage points over the past year.
About Amylyx Pharmaceuticals
AMLX stock →Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
Health Care · Biotechnology: Pharmaceutical Preparations · 136 employees
About Dyne Therapeutics
DYN stock →Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 289 employees
AMLX vs DYN FAQ
Which is bigger, Amylyx Pharmaceuticals or Dyne Therapeutics?
Amylyx Pharmaceuticals (AMLX) is larger, with a market capitalization of $3.44B compared with $2.98B for Dyne Therapeutics (DYN).
Which stock has performed better over the past year, AMLX or DYN?
AMLX returned +103.34% over the past 12 months, compared with +14.48% for DYN (price return, excluding dividends). Past performance does not predict future results.
Are Amylyx Pharmaceuticals and Dyne Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.